Multimodal Assesment of Alzheimer Patients

Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Jun 3, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Multimodal Assessment of Alzheimer Patients," aims to better understand the changes that occur in the brains of individuals with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD). The researchers want to find out how to detect Alzheimer's earlier, identify differences between healthy individuals and those with cognitive impairments, and understand how Alzheimer's disease uniquely affects the brain.

Participants in the study will go through a variety of tests, including memory and thinking assessments, brain scans using MRI, and other techniques like EEG, which measures brain waves. Some participants will also have their sleep patterns studied. To be eligible for the trial, individuals must have either MCI or AD and be between the ages of 23 and 740. Importantly, those with certain medical conditions, like early-onset Alzheimer's or other neurological disorders, will not be able to participate. This study is not currently recruiting participants, but it will offer valuable insights into Alzheimer's disease and cognitive impairment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • MCI and AD according to relevant ICD-criterias.
• • Control cohort is age and gender matched with other cohorts.
• Exclusion Criteria:
• • Uneligibility for any of the planned neuroimagery devices (MRI, EEG)
• • AD diagnosis before the age of 65 (Early-onset AD).
• • Brain tumor
• • Traumtic head injury
• • Earlier neurosurgery
• • Other neyrodegenerative diseases (i.e Parkinson and ALS)
• • Diseases related to inflammation and auto-immunity (i.e MS)